IZEA Announces Q3 2025 Earnings Results Conference Call

IZEA reported Q2 2026 revenue of $5.8M, down 36% YoY, and a net loss of $0.7M, as it shifts to larger enterprise accounts. Managed services bookings fell 19% YoY, while SaaS revenue declined 32%. The company has $46.6M in cash and no long-term debt. Management highlighted new enterprise wins and an active M&A pipeline, but noted macroeconomic uncertainty.

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( August 11, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, citing concerns over semaglutide's patent expiration and its impact on revenue. The stock, trading at 10.6x earnings, fell 2% post-call. Analysts debate whether the multiple reflects a bargain or undervalues future growth. Hedge funds increased holdings, while short interest remains low.

Halliburton (HAL) secured a multi-year contract from Eni (E) for the Cronos ultra-deepwater project in Cyprus, covering integrated drilling and well services. The deal aims to boost revenue per well and improve operational efficiency, though profitability depends on pricing and delivery costs. HAL's Q2 Europe/Africa revenue rose 19% sequentially, partly driven by regional activity.

Baird downgraded NIKE (NKE), Dick's (DKS), adidas, Rocky Brands, and VF Corp to Neutral, citing consumer spending concerns due to oil prices and interest rates. NIKE and DKS are interconnected, with NIKE products making up 31% of DKS's merchandise. DKS shares fell 30% in August after lowering full-year expectations. Hedge fund holdings in DKS increased, while NIKE saw a decline. Baird's report suggests potential structural demand weakness in the footwear segment.

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.